Evidence map›Paper›PMID 36090498›Full record

ArticleKidney international reports2022

Living Well With Kidney Disease and Effective Symptom Management: Consensus Conference Proceedings.

Connie M Rhee, Dawn Edwards, Rebecca S Ahdoot, James O Burton, Paul T Conway, Steven Fishbane, Daniel Gallego, Maurizio Gallieni, Nieltje Gedney, Glen Hayashida and 12 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 5 countries.

Connie M RheeDivision of Nephrology Hypertension and Kidney Transplantation, University of California Irvine, Orange, California, USA.
Dawn EdwardsForum of ESRD Networks Kidney Patient Advisory Council, New York, New York, USA.
Rebecca S AhdootDivision of Nephrology Hypertension and Kidney Transplantation, University of California Irvine, Orange, California, USA.
James O BurtonRenal Medicine, University of Leicester, Leicester UK.
Paul T ConwayAmerican Association of Kidney Patients, Washington, USA.
Steven FishbaneDonald and Barbara Zucker School of Medicine at Hofstra / Northwell Health, Great Neck, New York, New York, USA.
Daniel GallegoEuropean Kidney Patients Federation, Spain.
Maurizio GallieniDepartment of Biomedical and Clinical Sciences, Università di Milano, Milan, Italy.
Nieltje GedneyHome Dialyzors United (HDI), Washington, USA.
Glen HayashidaNational Kidney Foundation of Hawaii, Honolulu, Hawaii, USA.
Julie IngelfingerHarvard Medical School, Boston, Massachusetts, USA.
Merle Kataoka-YahiroUniversity of Hawaii at Manoa, Nancy Atmospera-Walch School of Nursing, Honolulu, Hawaii, USA.
Richard KnightAmerican Association of Kidney Patients, Washington, USA.
Joel D KoppleHarbor-UCLA Medical Center, Torrance, California, USA.
Latha KumarsawamiTanker Foundation, Chennai, India.
Mark B LockwoodDepartment of Biobehavioral Nursing Science, University of Illinois at Chicago, College of Nursing, Chicago, Illinois, USA.
Mariana MureaWake Forest School of Medicine, Winston Salem, North Carolina, USA.
Victoria PageNational Kidney Foundation of Hawaii, Honolulu, Hawaii, USA.
J Emilio SanchezUniversity Hospital of Cabueñes, Gijón, Spain.
Jacek C SzepietowskiDepartment of Dermatology, Venereology and Allergology, Medical University, Wroclaw, Poland.
Siu-Fai LuiHong Kong Kidney Foundation, Hong Kong, China.
Kamyar Kalantar-ZadehDivision of Nephrology Hypertension and Kidney Transplantation, University of California Irvine, Orange, California, USA.
University of California, Irvine · USAmerican Association of Kidney Patients · USNational Kidney Foundation · USHarvard University · USHospital Universitario De Cabueñes · ESNorthwell Health · USUCLA Medical Center · USUniversity of Hawaiʻi at Mānoa · USUniversity of Illinois Chicago · USUniversity of Leicester · GBUniversity of Milan · ITWake Forest University · USWroclaw Medical University · PL

Funding

Tracking and Evaluation CoreU54GM138062 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI SY, ANGELA U · 2021 to 2025
$15.5M
NIGMS NIH HHS U54 GM138062
6 · The paper itself

Abstract

Chronic kidney disease (CKD) confers a high burden of uremic symptoms that may be underrecognized, underdiagnosed, and undertreated. Unpleasant symptoms, such as CKD-associated pruritus and emotional/psychological distress, often occur within symptom clusters, and treating 1 symptom may potentially alleviate other symptoms in that cluster. The Living Well with Kidney Disease and Effective Symptom Management Consensus Conference convened health experts and leaders of kidney advocacy groups and kidney networks worldwide to discuss the effects of unpleasant symptoms related to CKD on the health and well-being of those affected, and to consider strategies for optimal symptom management. Optimizing symptom management is a cornerstone of conservative and preservative management which aim to prevent or delay dialysis initiation. In persons with kidney dysfunction requiring dialysis (KDRD), incremental transition to dialysis and home dialysis modalities offer personalized approaches. KDRD is proposed as the preferred term given the negative connotations of "failure" as a kidney descriptor, and the success stories in CKD journeys. Engaging persons with CKD to identify and prioritize their personal values and individual needs must be central to ensure their active participation in CKD management, including KDRD. Person-centered communication and care are required to ensure diversity, equity, and inclusion; education/awareness that considers the health literacy of persons with CKD; and shared decision-making among the person with CKD, care partners, and providers. By putting the needs of people with CKD, including effective symptom management, at the center of their treatment, CKD can be optimally treated in a way that aligns with their goals.

Indexed as

chronic kidney diseaseconservative managementperson-centered carequality of lifesymptom clustersunpleasant symptoms

Identifiers

PMID36090498
PMCPMC9459054
OpenAlexW4283751360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.